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surement withmore than one endpoint is the generation of a cardinal index/score.
Without the prioritization and weighting of multiple endpoints a deduction of
recommendationsmight be questionable.METHODS: A pilot study was conducted
to elicit patients’ preferences about antiviral therapy of chronic hepatitis C. For the
Discrete-Choice-Experiment (DCE), 7 attributes were selected with 3 Levels each.
Therefore an orthogonal, balanced and efficient design was used and results were
analysed with random effects logit models. RESULTS: Patients and experts priori-
tized the respective endpoints in almost the same order, but weighted them differ-
ently. Sustained-Virological-Response received the highest weight followed by fre-
quency of application (patients) or duration of therapy (experts).CONCLUSIONS:Aim
was to demonstrate how DCEs can be used to empirically determine which PREs
should be included in the efficiency frontier analysis. Further it is demonstrated
how such methods can be used to prioritize across such multiple efficiency fron-
tiers. The survey demonstrated how DCEs could be used to empirically determine
which PREs are important in antiviral treatment of chronic hepatitis C. The results
could be used for the development of innovative therapeutic schemes and new
drugs which could meet patients’ needs. For IQWiG purposes the weights of PREs
are included in the health economic evaluation.
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PERCEPTIONS ABOUT ’RAPID’ WARFARIN REVERSAL WITH FRESH FROZEN
PLASMA TO REDUCE THE INR: A NOVEL SURVEY METHODOLOGY
Petrozzino J1, Hoesche J2, Jones C2
1Compara Biomedical, Orlando, FL, USA, 2CSL Behring, King of Prussia, PA, USA
OBJECTIVES: To determine health care provider perceptions about timing of ’rapid’
warfarin reversal-related patient care events using novel survey methodology.
METHODS: Forty-eight adult and pediatric trauma centers were contacted to par-
ticipate in a direct-to-provider (DTP) survey. Participants were asked to provide
aggregate information about patients receiving fresh-frozen plasma (FFP) for acute
warfarin reversal. RESULTS: Nineteen to 25 health care professionals from 18 cen-
ters provided information by survey. Average perceptions of time needed to infuse
FFP under this setting (mean 4.6 hrs from time of triage; 95% CI 1.0 – 8.2 hrs) are
consistent with actual, published values. In contrast, average perceptions of time
needed for initial International Normalized Ratio (INR) normalization using FFP
(mean 5.8 hrs; 95% CI 2.8 – 8.8 hrs) underestimate actual, published values by 6 – 26
hrs. Health care providers perceived that relatively little cumulative time lapses
(1.6 hrs, on the average) for completing the first FFP infusion. There is little per-
ceived time lag between ordering and beginning the first FFP infusion (0.3 hrs, on
the average), consistent with actual, published values. There is substantial re-
ported time (an additional 3.0 hrs, on the average) needed to complete subsequent
FFP infusions, amounting to 52% of all perceived time lapsing for initial INR nor-
malization in this setting. CONCLUSIONS: DTP survey methodology appears to be
an efficient method for gathering clinical information for research purposes.
Healthcare providersmay have perceptions that are different frompublished stud-
ies, including inaccurate perceptions of the delay between the time FFP infusions
are completed and time of initial INR normalization. To our knowledge, this is the
first study to show that subsequent-to-first FFP dose infusion times account for the
majority of perceived INRnormalization time. Delays to treatment completionmay
present serious downstream consequences. Such perceptions may influence clin-
ical decision making, and warrant further analysis and investigation.
Urinary/Kidney Disorders – Clinical Outcomes Studies
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INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA
(CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION
Rubin JL1, Li S2, Yu H3, Dunning S2, Sato R3
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OBJECTIVES: To estimate CAP episode incidence and 30-day mortality rates in the
Medicare FFS population 65 years of age.METHODS: Claims data from the Medi-
care 5% sample were used to identify pneumonia diagnoses between July 1, 2007 to
June 30, 2008.We defined pneumonia hospitalizations as either Part A (PA) primary
discharge diagnosis (pdd) of pneumonia, or sepsis or respiratory failure as pdd plus
pneumonia as secondary diagnosis. Outpatient pneumonia was defined as a pneu-
monia diagnosis from PA outpatient or non-hospital sourced Part B, with claim for
chest x-ray within 14 days of pneumonia diagnosis. CAP episodes were defined as
being indexed on the first pneumonia claim date followed through the last pneu-
monia claim date preceded and followed by a 90 day clean period, respectively.
Episodes were defined as outpatient, unless beginning with or containing a CAP
hospitalization, in which case they were considered inpatient CAP episodes. We
further excluded evidence of hospitalization, long-term care and mechanical ven-
tilator use from claims within 14 days of the CAP index date. Incidence and mor-
tality were stratified by inpatient status and age. RESULTS: A total of 56,262 CAP
episodes were identified; 38.4% were inpatient. The average inpatient and outpa-
tient episode length was 32.7 days (SD 46.3) and 12.8 days (SD 27.6), respectively.
Corresponding incidence rates were 1,767/100,000 person-years for inpatient and
2,837/100,000 for outpatient CAP. Overall incidence rises with increasing age, rang-
ing from 2,786/100,000 person-years for those 65-69 to 8,449/100,000 for those 85.
Overall 30-day case-fatality was 5.6%; 8.5% for inpatient and 3.8% for outpatient
CAP. Case-fatality rates also increase with increasing age. CONCLUSIONS: The
overall incidence of CAP in the Medicare FFS population of 4,604/100,000 person-
years is substantial. These results suggest an estimated 1.13 million cases of CAP
and 63,000 CAP-related deaths annually among this population. CAP remains an
important public health burden in the United States.
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DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
AND META-ANALYSIS
Park T, Shamliyan TA
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: This study systematically reviews existing evidence to determine the
efficacy and adverse events of dutasteride, alone or in combination, versus a pla-
cebo or control, used for the treatment of benign prostatic hyperplasia (BPH).
METHODS:Medline and the Cochrane Library were searched for randomized con-
trolled trials that were longer than six months in duration. The study population
was men, aged 50 or older, with moderate and severe symptoms of BPH as deter-
mined by the International Prostate Symptom Score (IPSS) and clinical parameters
includingmaximumurinary flow rate (Qmax) and prostate volume. Ameta-analysis
with a random effects model was conducted to synthesize the findings of multiple
studies. Heterogeneity among the studies was assessed both graphically with for-
est plots and statistically with I2 statistics. RESULTS: Dutasteride was superior to
the placebo in reducing urinary symptoms measured by IPSS [weighted mean dif-
ference (WMD)  2.50, 95% confidence intervals (CIs)  2.91 to 2.09], prostate
volume (WMD12.90, 95% CIs14.27 to11.53) and in increasing Qmax (WMD
1.30, 95% CIs  0.99 to 1.61). However, risk ratios for any adverse events (1.27, 95%
CIs  0.99 to 1.62) and for drug-related adverse events (1.47, 95% CIs  0.77 to 2.79)
were not significantly different between those treated with dutasteride and those
in the control group. When dutasteride was administered with tamsulosin, the
reduction in IPSS scores and the increase in Qmax were greater than if the medica-
tions were administered alone, although prostate volume changed little. For both
BPH-related acute urinary retention (AUR) and BPH-related surgery, no significant
difference in risk ratio was observed between the combination group and the du-
tasteride group. CONCLUSIONS: Dutasteride can be used for those with moderate
to severe BPH symptoms when benefits from efficacy are considered to be greater
than the loss from adverse events.
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DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT
REPORTING SYSTEM DATABASE
Alhammad AM, Al Hawaj MA, Alsalman AJ, Alhashem YN, Harpe SE, Smith WR,
Brophy DF
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: The incidence of acute renal failure (ARF) is increasing. A substantial
proportion of these cases are due to drug-induced nephrotoxicity. Data from post-
marketing surveillance programs, like the FDA Adverse Event Reporting System
(AERS), can be useful in assessing the risk of adverse drug events. Our objective is to
describe reports with ARF (cases) and reports without ARF (non-cases) and out-
comes resulting from ARF using the AERS database. METHODS: Data were ex-
tracted from the AERS database from 2004–2009. All reports of cases and non-cases
were described and analyzed in term of suspected drugs, health outcomes, and
other characteristics. Descriptive statistics (frequencies and proportions) and Chi-
square tests were used. RESULTS: The AERS data used in this study represents
2,231,689 reports from 184 countries with 27,190 involving reports of ARF (cases).
There was approximately a two-fold increase in the percentage of reports of ARF
from 2004 to 2009 (n 3,594; 13% to n 6,104; 22%, respectively). Most reports were
submitted by manufacturers (cases  89%, non-cases 93%). The majority of re-
ports were for infants (cases  75%, non-cases  57%). In cases, drugs were the
primary suspect, the secondary suspect and concomitant in 18%, 14% and 66% of
reports, respectively. The five drugs with the highest reported frequencies of ARF
were rofecoxib, valacyclovir, metformin, simvastatin, and digoxin. Unfavorable
outcomesweremore likely to occur in cases than non-cases (death 24% vs. 12%, life
threatening condition 21% vs. 5%, initial/prolonged hospitalization 76% vs. 33%,
disability 6% vs. 4% and required intervention 4% vs. 2%; p-value  0.001, for all
comparisons). CONCLUSIONS: These preliminary findings present an overall pic-
ture of reports with ARF. These findings can be informative for regulatory author-
ities and healthcare professionals. Additional analyses with reporting odd ratios
(ROR) are needed to support these initial findings.
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CUMULATIVE EXPOSURE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
(NSAIDS) AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)
Yarger S1, Nwokeji E1, Trice S2, Chao S3, Devine J2, Potyk R2, Gutke G4, Bonnema A3
1Department of Defense/GDIT, Fort Sam Houston, TX, USA, 2Department of Defense, Fort Sam
Houston, TX, USA, 3Air Force Medical Support Agency, San Antonio, TX, USA, 4Healthcare
Informatics Division, San Antonio, TX, USA
OBJECTIVES: To examine the relationship between NSAID use and the progression
of CKD for a cohort of elderly patients within the military health system.
METHODS:All patients with at least one serum creatininemeasurement in each of
the time periods July 1–December 31, 2006 and July 1–December 31, 2008 with a
baseline estimated glomerular filtration rate (eGFR) representing CKD stage 2 or 3,
whowere 67 years of age, continuously eligible for TRICARE, and received care at
a military treatment facility were included in a retrospective database analysis.
Logistic regression analyses were used to explore associations between NSAID use
and rapid progression of CKDdefined as a decrease in eGFR of 15mL/min/1.73m2.
Covariates included age, gender, diabetes, hyperlipidemia, hypertension, and
NSAID exposure level. RESULTS: A total of 34,295 patients (median age 73.5, 50.2%
male) met the inclusion/exclusion criteria. A total of 14,576 patients had some
NSAID use, while 19,719 had no NSAID use. Rapid CKD progression occurred for
10.5% of no useNSAID patients (2,063 of 19,720), 11.2% of low tomediumNSAID use
patients (1,465 of 13,125), and 13.4% of high NSAID use patients (195 of 1,450).
Logistic regression results showed that stage 2-3 CKD patients with low tomedium
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NSAID use did not have an increased risk (stage 2 OR 1.002, CI 0.925-1.086; stage 3
OR 0.936, CI 0.782-1.122) of rapid CKD progression compared to the no NSAID ex-
posure group. Stage 2-3 CKD patients with high NSAID use trended toward, but did
not achieve a statistically significant increased risk (stage 2OR 1.185, CI 0.994-1.413;
stage 3 OR 1.276, CI 0.844-1.927) of rapid CKD progression. CONCLUSIONS: NSAID
exposure over a two year period was not associated with an increased risk of renal
dysfunction in our cohort of elderly patients with either stage 2 or 3 CKD.
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TREATMENT PATTERNS IN OVERACTIVE BLADDER: REAL-WORLD PATIENT
POPULATION
Ellsworth P1, Bavendam T2, Zou KH2, Mastey V2, Chen CI2
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OBJECTIVES: To assess the prescribing, switching, and dose-adjustment patterns
of overactive bladder (OAB) drugs in a real-world patient population.METHODS: A
retrospective analysis was conducted using the Medstat Marketscan databases,
which contain pharmacy claims for 28 million individuals across the US. Study
patients received anOAB drug prescription between April 1, 2009 and April 30, 2010
with continuous enrollment 6 months before the index date. Demographics, diag-
nosis rate, prescription fill dates, patients who switched to or from a given OAB
drug, and patients adjusting dosage were evaluated. RESULTS: A total of 214,721
patients had anOABprescription (mean age 65 y, 76%women), 23%were diagnosed
with OAB; 37% of patients resided in Southern, 35% in Northern Central, 18% in
Western, and 9% in Northeastern regions of the United States. Many patients
switched drug therapy during the study period; those receiving drugswithmultiple
dose options appeared to have oftenmade dose adjustments rather than switching
to a new agent (Table). For example, among patients prescribed solifenacin, 22% of
switches were to increase the dose and 39% were to decrease the dose. The pro-
portion of patients switching to another agent was higher among those receiving
oxybutynin, tolterodine ER, and solifenacin than with fesoterodine, darifenacin,
and trospium. Among 32,782 (15%) patients who switched OABmedication at least
once, the median (range) duration of time between filling their initial prescription
and either dose-adjusting or switching to a new agent was 139 (0–393) days and
they filled a median (range) of 4 (2–41) prescriptions before dose-adjusting or
switching. CONCLUSIONS: In this real-world population, patients take advantage
of the ability to adjust between multiple doses of drugs for which a flexible-dose
treatment option is available. Many patients switched drug therapy, which sug-
gests an opportunity to improve management of these patients and to identify an
optimal treatment pathway.
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LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
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OBJECTIVES: In patients undergoing chronic hemodialysis, unfractionated heparin
(UFH) is widely used for prevention of extracorporeal circuit thrombosis. Low-
molecular-weight heparin (LMWH)may have advantages in terms of bleeding risk.
The objective of this study was to review the effectiveness, safety and cost-effec-
tiveness of LMWH versus UFH in chronic hemodialysis to inform a hospital formu-
lary policy decision.METHODS:A systematic reviewwas conducted of randomized
(RCTs) and non-randomized trials (non-RCTs) published to April 2010 evaluating
the effectiveness, safety or cost-effectiveness of LMWHs for use in hemodialysis
compared with UFH. Outcomes included extracorporeal circuit thrombosis, bleed-
ing events, vascular access compression time, heparin-induced thrombocytope-
nia, and cost-effectiveness. Where possible, data was pooled via a random-effects
model. RESULTS:After reviewing 998 citations, 25 studieswere included (1 system-
atic review, 12 RCTs, 12 non-RCTs). Meta-analysis of RCTs demonstrated no statis-
tically significant differences between LMWH and UFH for bleeding (relative risk
(RR)0.70, p0.66) or compression time (weighted mean difference 2.49,
p0.31). Pooled RR for circuit thrombosis was 1.32 (p0.05) and 0.67 (p0.69) in
studies assessing the number of dialysis session and patients, respectively. Pooled
results for the non-RCTs were not significantly different between LMWH and UFH.
No studies evaluating the cost-effectiveness of LMWH versus UFH were identified,
however 4 cost analyses evaluated treatment costs. Despite higher drug acquisi-
tion costs with LMWH, overall costs were lower or comparable when considering
differences in nursing time associated with administration and monitoring.
CONCLUSIONS: LMWHdemonstrated no clear advantage over UFH in terms of effec-
tiveness or safety, but may result in lower or comparable overall hospital costs.
Urinary/Kidney Disorders – Cost Studies
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ECONOMIC EVALUATION OF CINACALCET VERSUS STANDARD TREATMENT IN
PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN MEXICO
Arocho R1, Ianazzo S2, Rivera Hurtado R3, Paniagua Sierra JR4
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a common complication of
chronic kidney disease (CKD). Cinacalcet is a drug that can regulate the levels of
plasma PTH, serum calcium and phosphorus in patients not controlled with stan-
dard treatment (vitamin D sterols and phosphate binders).We evaluated the use of
cinacalcet vs. standard treatment from a Public Mexican Healthcare perspective.
METHODS: A cost-effectiveness and a budget impact analyses were performed
with a simulation model over the whole patient=s lifetime considering 8-weeks
cycles. Efficacy data of cinacalcet were taken from published literature. Local mor-
tality data was adjusted for levels of Ca, P and PTH and for Relative Risk (RR) of
death in dialysis patients. Events considered are cardiovascular events, fractures
and parathyroidectomy. Costs are evaluated in local setting and account for drugs,
dialysis procedures and events. Patients were considered in the budget impact
(BIA) with a predicted uptake of cinacalcet in public sector of 7% in the first year.
RESULTS: The simulated patients in the cinacalcet group with respect to standard
treatment group experienced a mean (SD) increase in the average time in range
(TiR) of 1.91 (4.04) patient-years on all parameters and a lower rate of hospitaliza-
tion: RR were 0.43, 0.82 and 0.96 respectively for PTX, fracture and cardiovascular
hospitalization. Considering a price for the public sector of $ 3.29MXP /mg, the
average ICER for all parameters resulted $210,060MXP / TiR. BIA with cinacalcet
price for public sector predicted an extra expenditure of approximately $8 MXP
million in the first year considering drug costs and it represented the 0.2% of the
total health care expenditure for CKD. CONCLUSIONS: The use of cinacalcet in
comparison with standard treatment is a cost-effective strategy in patients with
SHPT and its use implies a low economic impact as compared to the total health-
care expenditure assigned to CKD in Mexico.
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KIT73 STUDY: DOES TYPE OF DONOR INFLUENCE LONG-TERM COSTS OF CARE?
RESULTS FROM POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN
PUBLIC HEALTH CARE SYSTEM (SUS)
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OBJECTIVES: The objective of this study was to estimate resource use and associ-
ated costs of care among recipients of kidney transplant according to donor type,
from the perspective of the Brazilian Public Health System (SUS). METHODS: The
KIT73 study was a retrospective observational study conducted at 7 transplant
centers, including 498 adult single kidney only transplant recipients from Jan/2004
to Jan/2005. Recipients were identified by donor type (living (LD) or deceased (DD)).
The DD group was further stratified by standard criteria donors (SCD) or expanded
criteria donors (ECD). Five-year costs were adjusted to 2004 at an annual discount
rate of 5% and converted to 2010 USD. A casemix group costing approachwas used
to determine average costs per day of hospitalization, stratified by cause (surgical
or clinical complication) and type (general ward, Intensive Care Unit (ICU).
RESULTS: All 498 recipients were included in the analyses. For both groups (LD or
DD), total inpatient costs of care were higher than total outpatient costs (excluding
medications) at 1 and 5 years. LD recipients incurred significantly lower costs than
DD recipients: mean (SD) costs per patient were USD1,460 (USD1,813) (LD) v0.s
USD2,785 (USD 3,615) (DD) (p0.0001) in the first year; USD288 (USD599) (LD) vs.
USD568 (USD1,540) (DD) (p0.01) in the fifth year. Comparison between SCD and
ECD groups, however, showed that the mean (SD) costs per patient were USD2,692
(USD3,616) (SCD) vs. USD3,767 (USD5,481) (ECD) (p0.377); USD545 (USD1,540) (SCD)
vs. USD810 (USD1,117) (ECD) (p0.146) in the fifth year. CONCLUSIONS: Recipients
of kidney transplants from living donors had lower costs over five years as com-
pared to recipients of transplants from deceased donors. Among recipients from
deceased donors, no statistical difference was observed in the comparison be-
tween ECD and SCD recipients.
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MEDICAL CARE SPENDING ASSOCIATED WITH CHRONIC KIDNEY DISEASE BY
STAGE OF DISEASE: A POPULATION-BASED STUDY
Taylor TN1, Salinitri FD2, Satterthwaite DW1
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OBJECTIVES: The objective of this research was to estimate expenditures attribut-
able to chronic kidney disease (CKD) by disease stage and to identify predictors of
variation in spending. METHODS: A retrospective analysis of de-identified health
insurance claims, laboratory data and pharmacy claims was performed using the
MarketScan Lab Results database for 2007. We calculated estimated glomerular
filtration rates (eGFR) using the 4 variable modification of diet and renal disease
(MDRD) equation and defined cases as those with an eGFR60mL/min/1.73m2.
Presence of comorbid conditions was base on ICD-9 codes reported on the claims.
Propensity score methods were used to match controls to cases. Data were ana-
lyzed using descriptive statistics and generalized linear models with a gamma
distribution and log-link controlling for disease stage, health plan type, comorbid
conditions, and demographic characteristics. RESULTS: A total of 2,436 cases were
identified with an eGFR of less than 60mL/min/1.73m2. We were able to match
controls to 2,223 (91.3%) of the identified CKD cases using propensity scores. Un-
adjusted expenditures were $10,353 (sd 23,262) for CKD cases compared to $9,310
(sd 22,703) for matched controls. After adjusting for health plan type, patient de-
mographic characteristics, and comorbid conditions, adjusted expenditures were
significantly greater for patients with CKD compared to matched controls depend-
ing on CKD stage. Expenditures by stage ranged from 8% higher for patients with
stage 3 disease to 62% higher for patients with stage 5 CKD compared to matched
controls. The key predictors of total treatment payments were disease stage, pres-
ence of comorbid conditions, age, and gender. CONCLUSIONS: Payments for med-
ical care attributable to CKD are significantly greater than medical care payments
for those who do not have CKD and vary importantly by disease stage. Interven-
tions that prevent or delay the progression of CKD have the potential to save
considerable resources.
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